|Home / Advance Research / End Duchenne Grant Award Program (GAP)||
End Duchenne Grant Award Program
PPMD has developed the EndDuchenne Grant Award Program in partnership with the National Institutes of Health (NIH) in an effort to ensure continuation of promising research and translation to human studies. The EndDuchenne Grant Award Program is a bridge grant provided by PPMD to promising research projects that receive scores beyond the current funding paylines of the National Institutes of Health (NIH) Institutes and Centers supporting Duchenne muscular dystrophy research. The goal and hope of this grant program is that bridge funding would accelerate promising research forward and enhance the success of competition for federal dollars toward new treatment development for Duchenne muscular dystrophy.
An applicant seeking support for this program must be employed at a for-profit or non-profit organization or institution and have submitted and received a complete review of an application to the NIH directed toward translation of research into human clinical studies specific for Duchenne muscular dystrophy within the last year. The applicant must have the resources to conduct the proposed research project and the organization/institution must have appropriate grant administrative capacities for the handling and disbursing of research funds.
The EndDuchenne Grant Award Program process builds from the NIH grant review process. Applicants are requested to provide the following materials: (See Application Face Sheet)
An Application Face Sheet should accompany the proposal.
For more information regarding this grant opportunity, please contact Sharon Hesterlee, Ph.D., Vice President Research at Sharon@ParentProjectMD.org or call 520-444-4462.
Number of awards each cycle is dependent on the number of applications, outcome of review and the availability of funds. PPMD is not obligated to make awards following each grant cycle.
The review of the End Duchenne Prize Grant addresses these key issues:
The review process will maintain strict confidentiality and attend to issues of conflict of interests. Applicants will be informed of disposition of the grant within a short time frame following the review. PPMD will make the final award decisions, in its sole discretion.
For more information on the End Duchenne Grant Award Program, please contact Sharon Hesterlee at 520-444-4462 or Sharon@parentprojectmd.org.
There has never been so much momentum in the Duchenne community. Help us keep moving forward by donating to fund CRISPR/Cas9 gene‑editing technology. Every gift to PPMD is being doubled until we raise $250,000—but we have to reach this goal by 12/31!